The Study Focuses on Gastric CancerNCT06506825
Construction and Application of Database of Hebei Provincial Gastric Cancer Collaborative Network Driven by Artificial Intelligence Technology
An observational study of The Study Focuses on Gastric Cancer, run by Qun Zhao at 1 site in China.
Trial summary
This clinical trial aims to construct and apply a collaborative network database for gastric cancer in Hebei Province, driven by artificial intelligence (AI) technology. The project seeks to integrate clinical data, genomic information, and treatment outcomes from multiple hospitals and research centers within the… Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- The Study Focuses on Gastric Cancer
- What is being tested?
- Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker
- How many people
- 30,000 participants
- Where
- 1 siteChina
- Study dates
- 1 Aug 2024to 31 Dec 2030
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- Adult, Older adult
Study population: All patients with gastric cancer
Who may be able to join
- All patients with gastric cancer
Who cannot join
- None
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site, 1 recruiting
- Recruiting
Department of General Surgery
Shijiazhuang, Hebei, 050011
Ping'an Ding, 031186095363, ding_ping_an@hebmu.edu.cn
Qun Zhao, Doctor
About this study
Official title: The Fourth Hospital of Hebei Medical University
This clinical trial aims to construct and apply a collaborative network database for gastric cancer in Hebei Province, driven by artificial intelligence (AI) technology. The project seeks to integrate clinical data, genomic information, and treatment outcomes from multiple hospitals and research centers within the region. By leveraging advanced AI algorithms, the database will facilitate comprehensive data analysis to identify novel biomarkers, optimize therapeutic strategies, and improve patient outcomes. This initiative will also support real-time data sharing and collaboration among healthcare providers, researchers, and policymakers, ultimately enhancing the overall management and treatment of gastric cancer in Hebei Province.
- Conditions
- The Study Focuses on Gastric Cancer
- Being tested
- Gastric Cancer AI-driven Data Integration Genomic Analysis Biomarker
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Gastric Cancer AI-driven Data Integration Genomic Analysis BiomarkerDiagnostic test
Enter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis
What is being measured
The primary outcome is the main question the study is designed to answer.
5-year overall survival
5-year overall survival
Measured: 2025-12-31
Secondary outcomes (1)
5-year recurrence-free survival
5-year recurrence-free survival
Measured: 2025-12-31
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jul 2024
- Study start1 Aug 2024 (estimated)
- Primary completion31 Dec 2030 (estimated)
- Study completion31 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for The Study Focuses on Gastric CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Retrospective
- Enrolment
- 30,000 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Qun Zhao
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor-investigator, Qun Zhao, Hebei Medical University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06506825
- Sponsor's protocol ID
- HBGCCN
- Status last verified
- Jul 2024
- First submitted
- 12 Jul 2024
- Last updated
- 18 Jul 2024
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Jul 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- The Fourth Hospital of Hebei Medical University
- ClinicalTrials.gov ID
- NCT06506825
- Acronym / sponsor ID
- HBGCCN
- Conditions
- The Study Focuses on Gastric Cancer
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 30,000 participants (estimated)
- Lead sponsor
- Qun ZhaoUniversity, hospital or other
- Study start
- 1 Aug 2024 (estimated)
- Primary completion
- 31 Dec 2030 (estimated)
- Study completion
- 31 Dec 2030 (estimated)
- First posted
- 18 Jul 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This clinical trial aims to construct and apply a collaborative network database for gastric cancer in Hebei Province, driven by artificial intelligence (AI) technology. The project seeks to integrate clinical data, genomic information, and treatment outcomes from multiple hospitals and research centers within the region. By leveraging advanced AI algorithms, the database will facilitate comprehensive data analysis to identify novel biomarkers, optimize therapeutic strategies, and improve patient outcomes. This initiative will also support real-time data sharing and collaboration among healthcare providers, researchers, and policymakers, ultimately enhancing the overall management and treatment of gastric cancer in Hebei Province.
Study design
- Observational model
- Cohort
- Time perspective
- Retrospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Age groups
- Adult, Older adult
- Study population
- All patients with gastric cancer
Key inclusion criteria (1 listed)
- All patients with gastric cancer
Key exclusion criteria (1 listed)
- None
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Gastric Cancer AI-driven Data Integration Genomic Analysis BiomarkerEnter the clinical and related test, examination and treatment information of all gastric cancer patients, and find risk factors that affect the prognosis | Diagnostic test | – |
Primary outcome
5-year overall survival
Time frame: 2025-12-31
5-year overall survival
1 secondary outcome
5-year recurrence-free survival
Time frame: 2025-12-31
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Jul 2024.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of The Study Focuses on Gastric Cancer, run by Qun Zhao at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 18 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
5-year overall survival (time frame: 2025-12-31). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Jul 2024.